C - Chemistry – Metallurgy – 07 – J
Patent
C - Chemistry, Metallurgy
07
J
C07J 73/00 (2006.01) C07J 75/00 (2006.01)
Patent
CA 2049881
A novel single-pot trialkylsilyl trifluoromethanesulfonate (R3Si-OTf) mediated process produces derivatives of 4-aza 3-keto steroids at the .alpha.-methylenic carbon through electrophilic substitution. These derivatives are useful in the preparation, through elimination of the substituent on the .alpha.-methylene carbon, of .DELTA.-1 olefin 4-aza 3-keto steroids which are potent inhibitors of 5-.alpha. reductase. 5.alpha.-dihydrotestosterone, which is the principal mediator of androgenic activity in some organs. Inhibitors of testosterone-5.alpha.-reductase have been shown to prevent or lessen symptoms of hyperandrogenic stimulation. Nayfe et al., [Steroids, 14, 269 (1969)] demonstrated in vitro that methyl 4-androsten-3-one-17.beta.-carboxylate was a testosterone-5.alpha.-reductase inhibitor. Voigt and Hsia, [Endocrinology, 92, 1216 (1973), Canadian Pat. No. 970,692], demonstrated that the above ester and the parent free acid, 4-androsten-3-one-17.beta.-carboxylic acid are both active inhibitors of testosterone-5.alpha.-reductase in vitro. Topical application of either testosterone or 5.alpha.-dihydrotesterone caused enlargement of the female hamster flank organ, an androgen dependent sebaceous structure. However, concomitant administration of 4-androsten-3-one-17.beta.-carboxylic acid, or its methyl ester, inhibited the response elicited by testosterone but did not inhibit the response elicited by 5.alpha.-dihydrotestosterone. These results indicated that the compounds are antiandrogenic by virtue of their ability to inhibit testosterone-5.alpha.-reductase. A number of 4-azasteroid compounds are known. See, for example, U.S. Pat. Nos. 2,227,876; 3,239,417; 3,264,301; and 3,285,918; French Pat. No. 1,465,544; Doorenbos and Solomons, J. Pharm. Sci. 62, 4, pp. 638-640 (1973); Doorenbos and Brown, J. Pharm. Sci., 60 8, pp. 1234-1235 (1971); and Doorenbos and Kim, J. Pharm. Sci. 63, 4, pp. 620-622 (1974). In addition, U.S. Patents 4,377,584 and 4,220,775 of Rasmusson et al., described a group of 4-aza-17.beta.-substituted-5.alpha.-androstan-3-ones which are said to be useful in the treatment of hyperandrogenic conditions. Furthermore, in U.S. Patent 4,760,071, Rasmusson et al., disclosed novel 17.beta.N-(monosubstituted)carbamoyl-4-aza-5.alpha.-androst-1- ene-3-ones, which are highly potent testosterone-5.alpha.- reductase inhibitors. The processes known in the art for preparing the aformentioned compounds generally include a step wherein a double bond is introduced into the lactam ring of the azasteroid. Thus, selenic anhydride oxidation [Back, T.G., J. Org. Chem., 46, 1442 (1981)], sulfoxide elimination [U.S. Patent No. 4,377,584; 4,220,775], and silylation mediated DDQ (2,3-dichloro-5,6-dicyano-1,4-benzoquinone) oxidation have all been used heretofore for the introduction of the .DELTA.-1 olefin functionality. The instant invention discloses a method whereby a powerful silylating reagent mediates regiospecific electrophilic substitution on the lactam ring to produce a versatile array of azasteroid derivatives substituted at the .alpha.-methylenic carbon. These derivatives are useful, through elimination of the added substituents, for making the .DELTA.1-olefin azasteroid derivative having potent 5-.alpha. reductase inhibitory activity.
Abramson Newton L.
Anderson Kevin
Douglas Alan W.
Karady Sandor
King Anthony On-Ping
Merck & Co. Inc.
Ogilvy Renault Llp/s.e.n.c.r.l.,s.r.l.
LandOfFree
Trialkylsilyl trifluormethanesulfonate mediated... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Trialkylsilyl trifluormethanesulfonate mediated..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Trialkylsilyl trifluormethanesulfonate mediated... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1542600